Switch theme
Sign up to access all valuation multiples
Luyan Pharma Co Ltd, formerly Luyan (Fujian) Pharma Co Ltd engages in the production, operation, distribution, and retail of human health products in China. It provides medical and health products.
2008
n/a
LTM Revenue n/a
LTM EBITDA n/a
$1.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Luyan Pharma has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Luyan Pharma achieved revenue of $2.7B and an EBITDA of $113M.
Luyan Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Luyan Pharma valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $2.7B | n/a | XXX | XXX | XXX |
| Gross Profit | $189M | $209M | XXX | XXX | XXX |
| Gross Margin | 7% | NaN% | XXX | XXX | XXX |
| EBITDA | $113M | n/a | XXX | XXX | XXX |
| EBITDA Margin | 4% | NaN% | XXX | XXX | XXX |
| Net Profit | $42.1M | $47.6M | XXX | XXX | XXX |
| Net Margin | 2% | NaN% | XXX | XXX | XXX |
| Net Debt | $543M | $597M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Luyan Pharma's stock price is CNY 8 (or $1).
Luyan Pharma has current market cap of CNY 3.0B (or $416M), and EV of CNY 7.7B (or $1.1B).
See Luyan Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.1B | $416M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Luyan Pharma has market cap of $416M and EV of $1.1B.
Luyan Pharma's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Luyan Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Luyan Pharma and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.1B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpLuyan Pharma's NTM/LTM revenue growth is n/a
Luyan Pharma's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Luyan Pharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Luyan Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Luyan Pharma and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 0% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 0% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 0% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 4% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| MedPlus India | XXX | XXX | XXX | XXX | XXX | XXX |
| Pague Menos | XXX | XXX | XXX | XXX | XXX | XXX |
| Droga Raia | XXX | XXX | XXX | XXX | XXX | XXX |
| Redcare Pharmacy | XXX | XXX | XXX | XXX | XXX | XXX |
| Oriola | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Luyan Pharma acquired XXX companies to date.
Last acquisition by Luyan Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Luyan Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Luyan Pharma founded? | Luyan Pharma was founded in 2008. |
| Where is Luyan Pharma headquartered? | Luyan Pharma is headquartered in China. |
| Is Luyan Pharma publicy listed? | Yes, Luyan Pharma is a public company listed on SHE. |
| What is the stock symbol of Luyan Pharma? | Luyan Pharma trades under 002788 ticker. |
| When did Luyan Pharma go public? | Luyan Pharma went public in 2016. |
| Who are competitors of Luyan Pharma? | Similar companies to Luyan Pharma include e.g. MedPlus India, Pague Menos, Droga Raia, Redcare Pharmacy. |
| What is the current market cap of Luyan Pharma? | Luyan Pharma's current market cap is $416M |
| Is Luyan Pharma profitable? | Yes, Luyan Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
